BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 9339934)

  • 1. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
    Dees EC; Shulman LN; Souba WW; Smith BL
    Ann Surg; 1997 Sep; 226(3):279-86; discussion 286-7. PubMed ID: 9339934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes.
    Ogawa Y; Nishioka A; Inomata T; Yokota N; Sasaki T; Terashima M; Yoshida S; Tanaka Y; Tohchika N
    Oncol Rep; 1999; 6(4):801-5. PubMed ID: 10373660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
    Shen K; Shen Z; Han Q
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):221-4. PubMed ID: 10920903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.
    Turner RR; Ollila DW; Krasne DL; Giuliano AE
    Ann Surg; 1997 Sep; 226(3):271-6; discussion 276-8. PubMed ID: 9339933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node dissection for breast cancer: a decision analysis of T1 lesions.
    Velanovich V
    Ann Surg Oncol; 1998 Mar; 5(2):131-9. PubMed ID: 9527266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imprint cytology of axillary lymph nodes in breast carcinoma following neoadjuvant chemotherapy.
    Jegaraj A; Kadambari D; Srinivasan K; Siddaraju N
    Acta Cytol; 2010; 54(5):685-91. PubMed ID: 20968156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Dominici LS; Sineshaw HM; Jemal A; Lin CC; King TA; Freedman RA
    Breast Cancer Res Treat; 2018 Jan; 167(2):555-566. PubMed ID: 28990127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer?
    Chua B; Ung O; Taylor R; Boyages J
    Breast J; 2003; 9(6):478-84. PubMed ID: 14616942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.